We are live on ! Find out more

2,403 hedge funds and large institutions have $180B invested in Pfizer in 2018 Q4 according to their latest regulatory filings, with 258 funds opening new positions, 780 increasing their positions, 1,126 reducing their positions, and 86 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 258 | Existing positions closed: 86

26% more funds holding in top 10

Funds holding in top 10: 260328 (+68)

7% more funds holding

Funds holding: 2,2562,403 (+147)

0.2% more ownership

Funds ownership: 75.71%75.91% (+0.2%)

3% less capital invested

Capital invested by funds: $185B → $180B (-$5.59B)

6% less call options, than puts

Call options by funds: $1.21B | Put options by funds: $1.28B

31% less repeat investments, than reductions

Existing positions increased: 780 | Existing positions reduced: 1,126

Holders
2,403
Holders Change
+147
Holders Change %
+6.52%
% of All Funds
53.54%
Holding in Top 10
328
Holding in Top 10 Change
+68
Holding in Top 10 Change %
+26.15%
% of All Funds
7.31%
New
258
Increased
780
Reduced
1,126
Closed
86
Calls
$1.21B
Puts
$1.28B
Net Calls
-$74.9M
Net Calls Change
-$251M
Name Holding Trade Value Shares
Change
Change in
Stake
CC
1026
Chicago Capital
Illinois
$3.25M +$482K +11,607 +17%
WSC
1027
Wellington Shields & Co
New York
$3.24M +$822K +19,806 +34%
APP
1028
Avantax Planning Partners
Iowa
$3.24M +$152K +3,652 +5%
RMSCM
1029
R.M. Sincerbeaux Capital Management
New York
$3.23M
HIC
1030
Holderness Investments Company
North Carolina
$3.23M +$60.5K +1,457 +2%
NNP
1031
Nachman Norwood & Parrott
South Carolina
$3.22M +$3.23M +77,816 New
PCA
1032
Providence Capital Advisors
North Carolina
$3.22M -$432K -10,414 -12%
GC
1033
Grimes & Company
Massachusetts
$3.22M -$198K -4,762 -6%
EHC
1034
Everett Harris & Co
California
$3.21M
RC
1035
Roundview Capital
New Jersey
$3.2M +$247K +5,951 +8%
BAM
1036
Blueshift Asset Management
New Jersey
$3.2M +$3.21M +77,252 New
ESB
1037
Essex Savings Bank
Connecticut
$3.19M +$3.2M +77,023 New
BWAM
1038
Boyd Watterson Asset Management
Ohio
$3.19M -$11.6K -279 -0.4%
PL
1039
Perpetual Ltd
Australia
$3.18M
CCA
1040
Checchi Capital Advisers
California
$3.17M -$309K -7,448 -9%
IHL
1041
Investment House LLC
California
$3.16M -$99.3K -2,391 -3%
FWM
1042
Foresight Wealth Management
Utah
$3.16M +$3.16M +76,215 New
BCM
1043
Boltwood Capital Management
California
$3.15M -$152K -3,653 -5%
WPW
1044
Winthrop Partners - WNY
New York
$3.15M -$5.89K -142 -0.2%
TA
1045
Tiedemann Advisors
New York
$3.15M +$740K +17,822 +31%
AAM
1046
Auxier Asset Management
Oregon
$3.15M -$166K -4,006 -5%
SFM
1047
Signet Financial Management
New Jersey
$3.13M +$12.8K +308 +0.4%
GIA
1048
Gargoyle Investment Advisor
New Jersey
$3.13M
PHS
1049
Pekin Hardy Strauss
Illinois
$3.12M +$599K +14,430 +24%
RWM
1050
Rench Wealth Management
Texas
$3.11M +$32.1K +773 +1%

PFE Hedge Fund Activity: Q4 2018 in Review

2,403 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q4 2018, worth a combined $180B — down 3% from $185B a quarter earlier.

Buyers outnumbered sellers: 258 funds opened new PFE positions and 86 closed out — a net gain of 172 holders — while 780 added to existing stakes and 1,126 trimmed.

The largest buyer was Capital World Investors, adding an estimated $1.77B. The largest seller was Longview Partners, cutting an estimated $721M.

  • 2,403 institutional investors held Pfizer (PFE) as of Q4 2018, up from 2,256 in Q3 2018.
  • Funds reported $180B of Pfizer stock for Q4 2018, down 3% quarter-over-quarter.
  • 258 funds opened new Pfizer positions in Q4 2018 and 86 closed out, a net change of +172 holders.
  • The largest Pfizer buyer in Q4 2018 was Capital World Investors, an estimated $1.77B added.
  • The largest Pfizer seller in Q4 2018 was Longview Partners, an estimated $721M sold.

Based on aggregated 13F filings for Q4 2018.